CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Endo Pharmaceuticals Solutions Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Endo Pharmaceuticals Solutions Inc.
1400 Atwater Drive
Phone: (617) 861-8444p:617 861-8444 Malvern, PA  19355  United States
Filed for Bankruptcy on 8/16/2022
This company was Merged or Acquired on 3/23/2009.
This company ceased filing statements with the SEC on 4/2/2009.
Case #22-22592, filed in the U.S. Bankruptcy Court for the Southern District of New York (White Plains)
This case is being Jointly Administered under the lead case filed for Endo International plc Case #22-22549.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Endo Pharmaceuticals Solutions Inc., formerly known as Indevus Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company’s products include SANCTURA and SANCTURA XR for overactive bladder (OAB), which it co-promotes with its partner Allergan, Inc. (Allergan); VANTAS for advanced prostate cancer; SUPPRELIN LA for central precocious puberty (CPP), and DELATESTRYL for the treatment of hypogonadism. Its advanced compounds are VALSTAR for bladder cancer, NEBIDO for hypogonadism, PRO 2000 for the prevention of infection by human immunodeficiency virus (HIV) and other sexually transmitted pathogens, and the octreotide implant for acromegaly and carcinoid syndrome. Endo Pharmaceuticals Solutions Inc. operates as a subsidiary of Branded Operations Holdings, Inc., owned by Par Pharmaceutical 2, Inc.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20089/30/2008YesYesYes-Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Business Names
Business Name
CPEC LLC
Endo Pharmaceuticals Solutions Inc.
IDEV
5 additional Business Names available in full report.

General Information
Outstanding Shares: 78,187,924 (As of 12/31/2008)
Shareholders: 578
Stock Exchange: NASD
Federal Tax Id: 043047911


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023